Review of macrolides and ketolides: Focus on respiratory tract infections

Drugs

Volumn 61, Issue 4, 2001, Pages 443-498

  Zhanel, G G ^a,b,c   Dueck, M ^b   Hoban, D J ^a,c   Vercaigne, L M ^b   Embil, J M ^a,c   Gin, A S ^b,c   Karlowsky, J A ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANTICOAGULANT AGENT; ASTEMIZOLE; AZITHROMYCIN; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; CYCLOSPORIN; DIGOXIN; DIRITHROMYCIN; DISOPYRAMIDE; ERGOT ALKALOID; ERYTHROMYCIN; FELODIPINE; FLURITHROMYCIN; KETOLIDE; MACROLIDE; METHYLPREDNISOLONE; MEVINOLIN; MIDAZOLAM; ROXITHROMYCIN; SUFENTANIL; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; VALPROIC ACID;

ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; NEUROTOXICITY; OTITIS MEDIA; OTOTOXICITY; PHARMACODYNAMICS; PHARMACOECONOMICS; PHARYNGITIS; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

HAEMOPHILUS INFLUENZAE; NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035059952     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161040-00003     Document Type: Review

References (296)

1. Erythromycin
2. Choosing the right macrolide antibiotic: A guide to selection
3. The new macrolides: Azithromycin and clarithromycin
4. Azithromycin: The first azalide antibiotic
5. Clinical relevance of intracellular and extracellular concentrations of macrolides
6. Novelties of the field of anti-infectives in 1997
7. Chemistry and mode of action of macrolides
8. Macrolide antibiotics
9. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: Comparison with that of azithromycin and roxithromycin
10. Design synthesis and characterization of ABT-773: A novel ketolide highly active against multidrug resistant pathogens
11. Molecular basis of ABT 773 activity against erm-containing macrolide resistant S. pneumonioe
12. Pharmacodynamics of macrolides, azalides, and streptogramins: Effect on extracellular pathogens
13. New directions for macrolide antibiotics: Pharmacokinetics and clinical efficacy
14. New macrolides: Expanded horizons for an old class of antibiotics
15. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin
16. New directions for macrolide antibiotics: Structural modifications and in vitro activity
17. Clarithromycin and azithromycin: New macrolide antibiotics
18. Clarithromycin: Review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles
19. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp.; its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
20. In vitro antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens
21. The in vitro activity of ABT 773 against Gram-positive and Gram-negative pathogens
22. Mechanism of action of spiramycin and other macrolides
23. Erythromycin
24. Ribosome-catalysed peptidyl transfer: Effects of some inhibitors of protein synthesis
25. Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes
26. Functional consequences of binding macrolides to ribosomes
27. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus
28. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004
29. RU 004: Preliminary studies on the mechanism of action
30. Mechanism of action for novel ketolide ABT 773
31. Interaction of macrolides and ketolides with the ribosome
32. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification
33. Erythromycin resistance by ribosome modification
34. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants
35. Inhibition of protein synthesis by streptogramins and related antibiotics
36. Ribosomal changes resulting in antimicrobial resistance
37. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria
38. Prevention of drug access to bacterial targets: Permeability barriers and active efflux
39. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
40. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae
41. Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae
42. Role of an energy-dependent efflux pump in plasmid pNE24-mediated resistance to 14- and 15-membered macrolides in Staphylococcus epidermidis
43. Novel mechanism of macrolide resistance in Streptococcus pneumoniae
44. B resistance phenotype
45. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin
46. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens
47. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study
48. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998
49. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides
50. Azithromycin: A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections
51. Clarithromycin: A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients
52. Comparison of macrolide antibiotics
53. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy
54. Azithromycin: The first of the tissue-selective azalides
55. In vitro activity of RU 64004, a ketolide antibiotic, against Grampositive bacteria
56. In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae
57. Telithromycin (HMR 3647) is highly active against Canadian pharyngeal isolates of Streptococcus pyogenes
58. The renaissance of the macrolides: New and changing roles in infectious diseases
59. An overview of the activity of clarithromycin against H. influenzae
60. Activity of clarithromycin compared to erythromcyin against Streptococcus pneumoniae isolated from blood cultures
61. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis
62. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay
63. In-vitro activity of dirithromycin in comparison with other new and established macrolides
64. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
65. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
66. Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin
67. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against Gram-positive cocci of known erythromycin susceptibility status
68. Activity of the ketolide telithromycin (HMR 3647) against erythromycin-resistant isolates of S. pneumoniae
69. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae
70. Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU-64004, a new ketolide, compared with susceptibilities to 16 other agents
71. B resistance phenotypes
72. The in vitro activity of ABT-773 against Gram-positive respiratory pathogens
73. Clinical microbiology of azithromycin
74. Azithromycin-spectrum of activity, pharmacokinetics, and clinical applications
75. In-vitro activity of the new ketolide antibiotic HMR 3647 against Gram-positive bacteria
76. Activity of HMR 3647 compared to 4-macrolides and pristinamycin against H. influenzae and M. catarrhalis by MIC
77. In vitro activity of the ketolide HMR 3647 and comparative macrolides against Streptococcus pneumonaie, Haemophilus influenzae and Moraxella catarrhalis isolated from 18 medical centres across Canada
78. The novel ketolide HMR 3647 shows high activity against Gram-positive cocci
79. In vitro activity of HMR 3647 against S. pneumoniae and H. influenzae analysed on the basis of erythromycin or cefuroxime susceptibitity
80. In vitro antibacterial activity of HMR 3647, a new ketolide antibiotic
81. In vitro activity of the new ketolide HMR 3647 against Gram-positive cocci either suceptible or resistant to erythromcyin
82. In vitro and in vivo antibacterial activities of HMR 3647 against penicillin-susceptible and -resistant Streptococcus pneumoniae
83. Ketolide (HMR 3647) in vitro activity on 4000 strains of Streptococcus pyogenes isolated in northern Italy
84. The novel ketolide HMR 3647 is highly active against worldwide isolates of Streptococcus pneumoniae and Streptococcus pyogenes
85. Antianaerobic activity of the ketolide HMR 3647 compared to 12 other compounds
86. In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens
87. The comparative in vitro activity of HMR 3647 against speciated coagulase-negative Stapyhylococcus spp
88. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
89. In vitro activity of a novel ketolide HMR 3647 and comparative macrolides against worldwide Haemophilus influenzae (HI) isolates
90. In vitro activity of the new ketolide HMR3647 in comparison with those of macrolides and pristinamycins against Enterococcus spp.
91. Activity of ABT 773 (a new ketolide) compared with 11 agents against H. influenzae and M. catarrhalis by MIC
92. Comparative in vitro antimicrobial activity of ABT 773 and tentative disk test interpretive criteria
93. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66674) and HMR 3004 (RU 64004)
94. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five β-lactams, clindamycin, and metronidazole
95. Roxithromycin: Review of its antimicrobial activity
96. In vitro activity of ABT-773 against 362 clinical isolates of anaerobic bacteria
97. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
98. In vitro susceptibilities of aerobic and facultative non-spore-forming Grampositive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials
99. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
100. In vitro activity of ketolides against mycoplasmas
101. Activity of telithromycin (HMR 3647) a new ketolide antimicrobial against human mycoplasmas
102. Intracellular activity of ABT 773 and other antimicrobial agents against Legionella pneumophila isolates
103. In vitro activity of ABT-773 a new ketolide antibiotic against Chlamydia pneumoniae
104. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial program
105. Alexander Project Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens findings of the Alexander Project 1992-1996
106. In vitro pharmacodynamic modelling of clarithromycin versus mefA and ermB macrolide resistant Streptococcus pneumoniae
107. Macrolides
108. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae
109. Tissue distribution of dirithromycin: Comparison with erythromycin
110. Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva
111. Comparative pharmacokinetics of macrolides
112. Relevance of the Alexander Project: Pharmacodynamic considerations
113. Pharmacokinetics and pharmacodynamics of newer macrolides
114. Roxithromycin: A pharmacokinetic review of a macrolide
115. Roxithromycin: A review of its activity, pharmacokinetic properties and clinical efficacy
116. The pharmacokinetics of azithromycin in human serum and tissues
117. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions
118. Azithromycin: A review of its use in paediatric infectious diseases
119. Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children
120. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections
121. Spiramycin, josamycin and rosaramicin
122. Spiramycin renaissance
123. Comparative pharmacology of josamycin and erythromycin stearate
124. Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers
125. Macrolides and host defences to respiratory tract pathogens
126. Phagocyte uptake and transport of azithromycin
127. The site concentrations of antimicrobial agents in the lung
128. Predicting the efficacy of antimicrobial agents in respiratory infections: Is tissue concentration a valid measure?
129. Distribution of clarithromycin and its metabolite (14-OH) in therapeutically relevant respiratory tract tissues and fluids
130. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans
131. The ketolide antimicrobial, HMR 3647, achieves high and sustained concentrations in broncho-pulmonary tissues
132. The penetration of macrolides into bronchial secretions
133. Uptake of flurithromycin by human polymorphonuclear phagocytes: Partial characterization of the entry mechanism
134. Penetration of roxithromycin into bronchial secretions
135. Tissue distribution of roxithromycin
136. Pulmonary disposition of azithromycin following a single 500 mg oral dose
137. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses
138. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects
139. Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic
140. Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxicillin
141. Azithromycine: Pharmacologie tissulaire
142. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration
143. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
144. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children
145. Penetration of clarithromycin into middle ear fluid of children with acute otitis media
146. Penetration of erythromycin into tonsillar tissue
147. Diffusion of roxithromycin into tonsillar tissue in children
148. Clarithromycin pharmacokinetics in sinus secretions of patients suffering from chronic maxillary sinusitis
149. The pharmacokinetics of azithromycin
150. Tissue-directed pharmacokinetics
151. Penetration of the macrolides into human polymorphonuclear leukocytes
152. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils
153. Uptake and intracellular activity of HMR 3647 in human phagocytic and non-phagocytic cells
154. Intraphagocytic location of macrolides
155. The bioavailability of HMR 3647, a new once-daily ketolide antimicrobial, is unaffected by food
156. Preclinical pharmacokinetic profile of ABT 773 in mouse, rat, monkey and dog
157. The importance of penetration of antimicrobial agents into cells
158. Intracellular activity, potential clinical uses of antibiotics: Several newer macrolides and quinolones that reach high levels in host cells are effective against intracellular pathogens
159. Investigation of dirithromycin and erythromycylamineerythromycylamine uptake by human neutrophils in vitro
160. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection
161. Intracellular distribution and activity of antibiotics
162. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
163. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
164. A comparative study of dirithromycin and erythromycin in bacterial pneumonia
165. Clinical efficacy of dirithromycin in patients with bacteremic pneumonia
166. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia
167. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: Comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate
168. Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis
169. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin
170. The effect of erythromycin on resolution of symptoms among adults with pharyngitis not caused by Group A Streptococcus
171. Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis
172. Pharyngitis Study Group Five days of erythromycin estolate versus ten days of penicillin V in the treatment of Group A streptococcal tonsillopharyngitis in children
173. Clinical comparison of cefaclor twice daily versus amoxicillin-clavulanate or erythromycin three times daily in the treatment of patients with streptococcal pharyngitis
174. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute respiratory tract infections
175. Pharmacodynamic studies of the ketolides HMR 3647 and 3004 on extracellular and intracellular Heliobacter pylori
176. The new ketolide, HMR 3647, achieves high and sustained concentrations in white blood cells in man
177. Choosing an antibiotic on the basis of pharmacodynamics
178. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
179. Pharmacokinetic contributions to postantibiotic effects: Focus on aminoglycosides
180. The new fluoroquinolones: A critical review
181. The new fluoroquinolones: Focus on respiratory infections
182. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
183. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
184. Postantibiotic effect: A review of in vitro and in vivo data
185. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract infections
186. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect
187. In vitro bactericidal activity of ABT 773 a new ketolide versus clarithromycin, azithromycin, ciprofloxacin, amoxicillin/clavulanate against penicillin/erythromycin sensitive and resistant S. pneumoniae and H, influenzae
188. Pharmacodynamic studies of HMR 3646 in vitro against respiratory tract pathogens
189. Post antibiotic effect (PAE) and bactericidal activity of HMR 3647 and other antimicrobial agents against respiratory pathogens
190. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia
191. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia
192. Microbiological efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia
193. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
194. Etiology and treatment of community-acquired pneumonia in ambulatory children
195. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: A retrospective study
196. Treatment of atypical pneumonia with azithromycin: Comparison of a 5-day and a 3-day course
197. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults
198. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis
199. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school
200. A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children
201. A multicenten open label trial of azithromycin for the treatment of children with acute otitis media
202. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children
203. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media
204. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media
205. Comparative study of once-weekly azithromycin and once-daily amoxicillin in prevention of recurrent acute otitis media in children
206. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion
207. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: Results of a multicenter, open comparative study
208. Paediatric Azithromycin Study Group Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis
209. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of Group A beta-hemolytic streptococcal pharyngitis in children
210. Azithromycin versus cefaclor in the treatment of pediatric patients with acute Group A beta-hemolytic streptococcal tonsillopharyngitis
211. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children
212. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis
213. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults
214. An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis
215. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections
216. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections
217. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections
218. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections
219. Once-daily, 3-day azithromycin versus a three-timesdaily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: Results of a randomized, double-blind comparative study
220. Clarithromycin versus amoxycillin-clavulanic acid in the treatment of communityacquired pneumonia
221. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
222. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbations of chronic bronchitis
223. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis
224. Randomized controlled study of clarithromycin versus cefaclor suspensions in the treatment of acute otitis media in children
225. Comparative study of the safety and efficacy of clarithromycin and amoxicillin clavulanate in the treatment of acute otitis media in children
226. Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis
227. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis
228. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis
229. Clarithromycin versus cefaclor in lower respiratory tract infections
230. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
231. Use of flurithromycin ethylsuccinate in infections of the lower airways due to sensitive germs: Multicenter comparative study with clarithromycin
232. Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis
233. A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease
234. Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis
235. Oral therapy with flurithromycin in ear, nose and throat infections
236. Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
237. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia
238. Efficacy of roxithromycin in the treatment of mycoplasma pneumonia
239. Oral empiric treatment of community-acquired pneumonia: A multicenter, doubleblind, randomized study comparing sparfloxacin with roxithromycin
240. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis
241. Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis
242. Roxithromycin 150mg b.i.d. versus amoxycillin 500mg/clavulanic acid 125mg t.i.d. for the treatment of lower respiratory tract infections in general practice
243. Antimicrobial treatment of community acquired pneumonia in adults: A conference report
244. Penicillin- and cephalosporinresistant Streptococcus pneumoniae. Emerging treatment for an emerging problem
245. Comparative efficacies of erythromycin-sulfisoxazole and cefaclor in acute otitis media: A double blind randomized trial
246. Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children
247. Randomized controlled trial of 3 versus 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis
248. Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion: A meta-analytic attempt to resolve the brouhaha
249. HMR 3647: Activity against L. pneumophila serogroup 1 (LP) in monocyte-derived macrophages and in experimental guinea pig infection models
250. HMR 3647 Treatment of β-lactamase positive Haemophilus influenzae Type B experimental pneumonia in immunocompetent mice
251. Efficacies of ABT 773 and HMR 3647 against respiratory pathogens causing acute systemic infections in mice and lung infections in rats
252. In vivo activity of HMR 3647, a novel ketolide highly active against respiratory pathogens
253. Efficacies of ABT 773 and azithromycin against experimental rat lung infections caused by Streptococcus pneumoniae
254. Empiric antibiotic selection criteria for respiratory infections in pediatric practice
255. Practical considerations and guidelines for the management of community-acquired pneumonia
256. Communityacquired pneumonia in adults: Guidelines for management
257. Summary of Canadian guidelines for the initial management of community acquired pneumonia: An evidence-based update by the Cana dian Infectious Disease Society and the Canadian Thoracic Society
258. Antipneumococcal activity of HMR 3647, a new ketolide, compared to other drugs, by time-kill
259. Acute otitis media: Management and surveillance in an era of pneumococcal resistance. Drug-resistant Streptococcus pneumoniae therapeutic working group
260. Managing otitis media: A time for change
261. Acute otitis media in the 1990s: The impact of antibiotic resistance
262. Management of pediatric patients with Group A betahemolytic Streptococcus pharyngitis: Treatment options
263. Optimum treatment of streptococcal pharyngitis
264. Classification, diagnosis and treatment of sinusitis: Evidence-based clinical practice guidelines
265. A practical guide for the diagnosis and treatment of acute sinusitis
266. Adverse effects of macrolide antibacterials
267. Clinical and financial impact of intravenous erythromycin therapy in hospitalized patients
268. Intravenous azithromycin-induced ototoxicity
269. Clinical toleration and safety of azithromycin
270. Drug associated hepatic reactions in New Zealand: 21 Years experience
271. An evaluation of tolerance of roxithromycin in adults
272. Comparison of spiramycin with erythromycin for lower respiratory tract infections
273. Pharmacokinetic drug interactions of macrolides
274. Azithromycin versus erythromycin for community-acquired pneumonia: A cost minimization analysis
275. The new macrolide antibiotics: Use them carefully
276. Drug interactions with azithromycin and the macrolides: An overview
277. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
278. Macrolide antibacterials: Drug interactions of clinical significance
279. Macrolides versus azalides: A drug interaction update
280. Erythromycin: Drug interactions
281. Azithromycinrelated toxin effects of digitoxin
282. Azithromycin drug interactions
283. Economic analysis of antibiotic regimens used in the treatment of pharyngitis: A prospective comparison of azithromycin versus roxithromycin
284. Economic analysis of treatment with roxithromycin in comparison with erythromycin patients with lower respiratory tract infections
285. Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study
286. Streamlining antimicrobial therapy for lower respiratory tract infections
287. Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media
288. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA
289. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media
290. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae
291. Haemophilus influenzae and Moraxella catarrhalis from patients with communityacquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
292. A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens
293. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in Group A streptococci in Finland